Harrison Seth Loring 4

What Happened

• Director Seth Loring received a grant of a derivative equity award covering 17,786 shares of Stoke Therapeutics on June 3, 2026. The reported acquisition price is $0.00 (derivative award), so no cash was paid by the insider at grant.

Key Details

• Transaction date: 2026-06-03; Form 4 filed: 2026-06-05 (timely within the usual 2-business-day window).
• Award type: Reported as a derivative (option/award) with $0.00 acquisition price.
• Amount: 17,786 shares/units.
• Vesting: The award “shall vest in full” on the earlier of (i) June 3, 2027 or (ii) the issuer’s next annual meeting of stockholders, subject to continued service (per filing footnote).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• No 10b5-1 plan, cashless exercise, tax withholding, or late-filing flag disclosed in this filing.

Context

• This is a grant of an equity award (derivative) rather than an open-market purchase or sale. Such grants are common for board compensation and do not by themselves indicate buying or selling pressure. The award vests in roughly one year or at the next annual meeting, meaning the economic interest and potential transferability may be restricted until vesting.